Asthma Clinical Trials

Find Asthma Clinical Trials Near You

A Prospective, Multicenter, Cluster-Randomized Trial to Evaluate the Impact of Guideline-Directed Medical Therapy in Uncontrolled Asthma Patients Receiving Medium-to-High Dose Inhaled Corticosteroids Plus Long-acting β2 Agonist

Status: Recruiting
Location: See all (20) locations...
Intervention Type: Behavioral
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The primary objective of this study is to evaluate whether GDMT can bring significant benefits to disease management in uncontrolled asthma patients receiving medium- to high-dose ICS-LABA. * The intervention period will be up to 48 weeks; * The frequency of follow-up is every 12 weeks.

Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: f
View:

• Sign the informed consent form before any study-related procedures;

• Age 18-75 years (inclusive) at Visit 0;

• Have a written diagnosis of asthma for more than 6 months prior to Visit 0, and have evidence of reversible airflow limitation prior to Visit 0. Evidence of reversible airflow limitation includes: post-bronchodilator increase in Forced Expiratory Volume in 1 second (FEV1) of ≥12% and an absolute increase of ≥200 mL, or average daily diurnal Peak Expiratory Flow (PEF) variability \>10%, or an increase in FEV1 of ≥12% and an absolute increase of ≥200 mL compared to baseline after 4 weeks of treatment containing ICS, or a positive bronchial provocation test record. If no prior record exists, reversible airflow limitation must be confirmed and documented via a bronchodilator test during Visit 0;

• Under the usage of MD/HD ICS-LABA;

• Experienced one or more exacerbations within the past year;

⁃ Exacerbation is defined as meeting any of the following criteria:

• Use of systemic corticosteroids (or a temporary increase in the stable dose of baseline oral corticosteroids) for at least 3 days; a single injection of a depot long-acting corticosteroid can be considered equivalent to a 3-day course of systemic corticosteroids;

• An emergency department or urgent care site visit for asthma (defined as being evaluated and treated in the emergency department or urgent care site for \< 24 hours) requiring the use of systemic corticosteroids for at least 3 days (as described above);

• Hospitalization for asthma (defined as admission to a hospital and/or being evaluated and treated in a healthcare facility for ≥ 24 hours).

Locations
Other Locations
China
Research Site
NOT_YET_RECRUITING
Chengdu
Research Site
RECRUITING
Chifeng
Research Site
NOT_YET_RECRUITING
Dongyang
Research Site
NOT_YET_RECRUITING
Hefei
Research Site
NOT_YET_RECRUITING
Hefei
Research Site
NOT_YET_RECRUITING
Hengyang
Research Site
NOT_YET_RECRUITING
Heze
Research Site
NOT_YET_RECRUITING
Jiaxing
Research Site
NOT_YET_RECRUITING
Langfang
Research Site
NOT_YET_RECRUITING
Meizhou
Research Site
NOT_YET_RECRUITING
Quanzhou
Research Site
NOT_YET_RECRUITING
Shanghai
Research Site
NOT_YET_RECRUITING
Shiyan
Research Site
NOT_YET_RECRUITING
Tai’an
Research Site
NOT_YET_RECRUITING
Ürümqi
Research Site
NOT_YET_RECRUITING
Xi'an
Research Site
NOT_YET_RECRUITING
Yantai
Research Site
NOT_YET_RECRUITING
Yongzhou
Research Site
NOT_YET_RECRUITING
Yunnan
Research Site
NOT_YET_RECRUITING
Zhanjiang
Contact Information
Primary
AstraZeneca Clinical Study Information Center
information.center@astrazeneca.com
1-877-240-9479
Time Frame
Start Date: 2026-09-05
Estimated Completion Date: 2028-04-30
Participants
Target number of participants: 540
Treatments
Experimental: Intervention group
The intervention will be implemented at the hospital level.
No_intervention: Control group
No intervention action will be taken at hospital level, even patient level.
Related Therapeutic Areas
Sponsors
Leads: AstraZeneca

This content was sourced from clinicaltrials.gov

Similar Clinical Trials